Skip to main content

Table 2 Baseline characteristics and treatment information

From: Comparative effects of recombinant human brain natriuretic peptide and dobutamine on acute decompensated heart failure patients with differsent blood BNP levels

Characteristics High BNP group Extra-high BNP group
  Dobutamine (n = 30) rhBNP (n = 28) P value Dobutamine (n = 23) rhBNP (n = 23) P value
Age (y) 63 ± 13 65 ± 13 0.495† 68 ± 14 67 ± 12 0.709†
Male/female 19/11 18/10 0.843‡ 15/8 16/7 0.935‡
HF etiology
 IDC 13 11 0.963‡ 10 12 0.768‡
 CHD 8 10 0.645‡ 10 8 0.763‡
 FVM 2 1 1.000§ 0 1 1.000§
 HHD 1 2 0.605§ 0 1 1.000§
 Valvulopathy 6 4 0.732§ 3 1 0.608§
 NHYA    0.645‡    0.489§
 III 8 10   0 2  
 IV 22 18   23 21  
Concomitant medications
 ACEI 14 16 0.593‡ 14 12 0.766‡
 ARB 12 7 0.349‡ 5 8 0.513‡
 Digitalis 24 23 0.899‡ 18 20 0.699§
 β-blockers 11 14 0.448‡ 4 6 0.722§
Spironolactone
 20 (mg/d) 15 18 0.405‡ 11 6 0.324‡
 40 (mg/d) 10 8 0.914‡ 10 12 0.768‡
Average dosage 28.0 ± 10.0 26.2 ± 9.4 0.500† 29.5 ± 10.2 33.3 ± 9.7 0.243†
Furosemide (mg/d)
 20 (mg/d) 12 15 0.440‡ 7 4 0.328§
 40 (mg/d) 11 8 0.707‡ 11 9 0.766‡
 80 (mg/d) 2 3 0.665§ 3 5 0.699§
 Average dosage 33.6 ± 17.0 33.1 ± 19.5 0.919† 39.0 ± 19.5 46.7 ± 22.8 0.267†
  1. †Unpaired t-test; ‡Chi-square test; §Fisher exact test.
  2. Abbreviations: ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, BNP brain natriuretic peptide, CHD coronary heart disease, HF heart failure, HHD hyperthyroid heart disease, IDC idiopathic dilated cardiomyopathy, NHYA New York Heart Association, rhBNP recombinant human brain natriuretic peptide. Values are expressed as number or mean ± SD.